RARE vs RNXT · rev $560.2M vs rev $266.0K
Ultragenyx (RARE) versus RenovoRx Inc (RNXT) — a side-by-side from cached financials, not a winner call.
Ultragenyx (RARE) is a biotechnology company listed on US.
RenovoRx Inc (RNXT) is a biotechnology company listed on US.
Latest reported RARE revenue for 2024-12-31 was $560.2M. Net income was -$569.2M. Revenue was up 29.0% from 2023-12-31 to 2024-12-31. RARE currently screens at market cap $2.79B.
Latest reported RNXT revenue for 2025-09-30 was $266.0K. Net income was -$2.9M. Revenue was down 37.0% from 2025-06-30 to 2025-09-30. RNXT currently screens at market cap $47.0M.
RARE currently screens at market cap $2.79B. RNXT currently screens at market cap $47.0M.
Not investment advice. Open the RARE and RNXT stock pages for the full models.
Not investment advice.